Pipeline
ECN0424
obesity
Obesity is a disease that can cause metabolic syndrome, cardiovascular diseases, respiratory diseases, and even cancer in high risk groups.
The majority of comparable drugs developed to date have failed, with development and sales suspended due to side effects. BHD1028, with 15 amino acids designed to have high affinity with Adipo R1, an adiponectin receptor, was designed to treat obesity without causing side effects by using a peptide that has been pegylated in the N terminal.
BHD1028 has high affinity of 10 µM in AdipoR1, and by checking genes related to the AMPK cell signal delivery system in muscle cells with active metabolism, it was confirmed to be superior to other drugs targeting the same receptor (ADP355).
Activation of signal delivery system involved in lipolysis by BHD1028
BHD1028 activates the signal delivery system that promotes the proliferation of mitochondria, which plays a pivotal role in lipid oxidation and energy metabolism in cells.
What is obesity?
Obesity refers to an excessively large amount of fat accumulated in the body, and is a high-risk disease that can cause metabolic syndrome, cardiovascular diseases, respiratory diseases, and inflammation in various areas of the body known to cause many diseases, and even cancer.
The fundamental cause of obesity is the inability to burn calorie intake, causing it to accumulate as body fat, and this prevents the metabolism process from functioning normally due to insulin resistance.
BHD1028’s mechanism of action in obesity
BHD1028 promotes the oxidation of free fatty acids and increases the activity of mitochondria, which are essential organelles for energy metabolism, by stimulating the adiponectin receptors AdipoR1 and AdipoR2 on the surface of cells.
With this activation, the efficient consumption of calories with a high body fat decomposition rate can be expected, and obesity can be treated by reducing weight via increased basal metabolism without excessive dietary control.
Competitiveness of BHD1028 in treating obesity
Most obesity therapeutics developed to date have been discontinued due to various side effects (cardiovascular diseases, reduced appetite, drop in kidney function, lethargy, etc.).
Existing drugs are effective in lowering weight by reducing the amount of food intake via central nervous system activities that control the sensations of fullness and appetite, but BHD1028 induces weight loss through increased basal metabolism by promoting increased oxidation of fat and energy metabolism in cells, enabling healthy obesity treatment without side effects being experienced.